Annual jab for HIV protection passes trial hurdle
Lenacapavir, which stops HIV from replicating inside cells, has passed early safety tests.
Lenacapavir, which stops HIV from replicating inside cells, has passed early safety tests.
Data from half-a-million people was assessed by the University of Aberdeen research team.
It can be taken at home on a daily basis, but it is only patients for who have tried all other options.
This is The Takeaway from today’s Morning Brief, which you can sign up to receive...
Listen and subscribe to Opening Bid on Apple Podcasts, Spotify, YouTube, or wherever you find...
Photo: Spencer Platt (Getty Images) Stocks ended lower on Tuesday, extending Monday’s rout, as President...
The London Stock Exchange dropped for a sixth session in a row when markets opened this morning.
On August 18, 2022, Praxis Tech, a paytech company based in Cyprus, announced its partnership...
If you’re feeling overwhelmed but don’t quite have the willpower to curb your online habit, your phone can help you manage your time online.